A MULTICENTER, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF AL002 IN PARTICIPANTS WITH ALZHEIMER*S DISEASE - AL002-LTE

Alector0 个研究点目标入组 4 人开始时间: 待定最近更新: 2024年4月9日

适应症

试验速览

阶段: 2 期
状态: 尚未招募
发起方
入组人数: 4

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. The participant has completed the Planned Treatment Period in the AL002-2
•study. Completion of the Planned Treatment Period is defined as any participant
•who did not prematurely and permanently discontinue IMP in the AL002-2 study.
•2. The participant is willing and able to give informed consent. Where local
•regulations permit inclusion of participants deemed not able to provide
•informed consent, a legally authorized representative must provide informed
•consent on his or her behalf, and the participant must provide assent, in
•accordance with the local regulations, guidelines, and institutional review
•board or independent ethics committee.
•3. The participant has availability of a person (*study partner*) who, in the
•Investigator*s opinion, has frequent and sufficient contact with the
•participant (eg, at least 10 hours per week of in person contact), is able to
•provide accurate information regarding the participant*s cognitive and
•functional abilities, agrees to provide information at clinic visits (which
•require partner input for scale completion), and signs the necessary consent
•a. The study partner must have sufficient cognitive capacity, in the
•Investigator*s opinion, to accurately report upon the participant*s behavior,
•cognitive, and functional abilities. The study partner should be in
•sufficiently good general health, in the Investigator*s opinion, to have a high
•likelihood of maintaining the same level of interaction with the participant
•and participation in study procedures throughout the study duration.
•b. Every effort should be made to have the same study partner participate
•throughout the duration of the study, and to have the same study partner as in
•the parent study.
•4. The participant and study partner are fluent in the language of the tests
•used at the study site as assessed by site personnel.
•5. The participant is willing and able to complete all aspects of the study
•(including MRI, optional LP, genotyping, and optional PET imaging, as
•applicable). The participant should be capable of completing assessments either
•alone or with the help of the study partner.
•6. The participant has adequate visual and auditory acuity, in the
•Investigator*s opinion, sufficient to perform the neuropsychological testing
•(corrective lenses and hearing aids are permitted).
•7. Participant agrees not to donate blood or blood products for transfusion for
•the duration of the study and for 1 year after the final dose of study drug.
•Inclusion criteria for participants in the optional tau PET imaging assessment
•with [18F]MK-6240 only:
•8. Participant has not had excessive radiation exposure prior to enrollment in
•the trial, as defined by local standards.
•9. [18F]MK-6240 is available to the PET imaging center based on manufacturing
•distribution network and local regulations.
•Inclusion criteria for participants in the optional longitudinal amyloid PET
•imaging assessment only:
•10. Participant has not had excessive radiation exposure prior to enrollment in
•the trial, as defined by local standards.
•11. An approved amyloid radiotracer is available to the PET imaging center
•based on manufacturing distribution network and local regulations.
•12. For at-home and in-clinic participation, participant must have the
•linguistic proficiency to complete the proposed assessments

排除标准

•Participants deemed not able to provide consent or assent by the Investigator
•or by local regulations.
•2. Participants who were prematurely and permanently discontinued from
•treatment in the parent
•study for safety reasons.
•3. The participant has MRI evidence of:
•a. more than 2 lacunar infarcts.
•b. Any territorial infarct greater then 1 cm3.
•c. White matter hyperintense lesions on the FLAIR sequence that correspond to
•an overall Fazekas score of 3.
•d. Participants who have an increase in their number of microbleeds, since the
•previous screening/ baseline MRI in the AL002-2 study and >5, should be
•discussed with the Medical Monitor.
•e. Participants who have developed ARIA-E and ARIA-H in the parent study and
•who were permitted to continue dosing according to the ARIA management
•guidelines, will not be excluded from participation in the AL002-LTE, on the
•basis of microbleeds or hemosiderosis.
•4. Participation in the AL002-LTE is deemed inappropriate for any reason per
•Investigator discretion.

研究者

发起方

Alector

相似试验

进行中（未招募）

1 期

A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's DiseaseEarly Alzheimer's DiseaseMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2022-002987-57-PLAlector, Inc.190

进行中（未招募）

1 期

EUCTR2022-002987-57-NLAlector, Inc.190

进行中（未招募）

1 期

EUCTR2022-002987-57-DEAlector, Inc.190

进行中（未招募）

不适用

Oral Revatio in Pediatric PAH - Long-term follow-on Study to A1481131.MedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary Arterial Hypertension

EUCTR2005-000963-25-Outside-EU/EEAPfizer Limited, Ramsgate Road, Sandwich, Kent, UK220

进行中（未招募）

不适用

A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil in the Treatment of Subjects Who Have Completed Study A1481131 - N/APulmonary Arterial Hypertension

EUCTR2005-000963-25-FIPfizer Limited, Ramsgate Road, Sandwich, Kent, UK185